This activity has expired.

Vulvodynia: A Common and Under-Recognized Pain Disorder in Women and Female Adolescents -- Integrating Current Knowledge into Clinical Practice

Release Date: April 01, 2016
Expiration Date: April 17, 2017

This educational activity is provided by Dannemiller and the National Vulvodynia Association.
DannemillerNational Vulvodynia Association

Intended Audience

This activity was developed for medical professionals who routinely care for women and adolescent girls.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Recognize vulvodynia as a prevalent, misdiagnosed, and under-researched chronic pain disorder affecting millions of women and adolescent girls

  • Define vulvodynia and its subtypes

  • Summarize what is known about the pathophysiology of vulvodynia

  • Identify the infectious, inflammatory, neoplastic and neurologic disorders that need to be ruled out in order to make a diagnosis of vulvodynia

  • Perform a comprehensive exam to diagnose the condition

  • Implement an individualized, multidisciplinary treatment regimen

Statement of Need

Although vulvodynia (chronic vulvar pain) was once considered a rare disorder affecting only middle-aged Caucasian women, NIH-funded population-based research studies have shown that it is highly prevalent, affecting adolescents and women of all ages and ethnicities. One epidemiological study found that it affects about 16 percent of U.S. women at some point in their lives. Because vulvodynia symptoms mimic those of common vulvovaginal infections and there are typically no visible abnormalities, adolescents and women with vulvodynia are often misdiagnosed. It can take many months or even years to be properly diagnosed, which leads to increased pain and emotional distress, and impaired quality of life among sufferers. To rectify this situation, the NVA created this tutorial to promote prompt diagnosis and appropriate treatment for vulvodynia patients.

Method of Participation

This activity should take approximately one hour to complete. Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive credit for this activity, participants must complete the post-test with a passing score of 80% and then complete the evaluation. Credit is provided through March 31, 2018. No credit will be given after this date. There is no fee to participate in this activity.

In the event you have questions about this activity or are unable to retrieve the certificate, please email cme@dannemiller.com and a certificate will be emailed within 2 weeks.

System requirements

  • Computer, tablet, or smartphone with internet access
  • Web browser (Chrome, Firefox, IE 8+) with JavaScript enabled

Accreditation

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Dannemiller and the National Vulvodynia Association. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.Dannemiller designates this [live activity / enduring material] for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Dannemiller is a provider approved by the California Board of Registered Nursing, Provider Number 4229. This activity has been approved for 1.0 contact hours. CBRN credit is not accepted by the Michigan and Utah State licensing boards.

Faculty

  • Dr. Jacob Bornstein
  • Dr. Andrew Goldstein
  • Dr. Ruby Nguyen
  • Dr. Colleen Stockdale
  • Dr. Pamela Morrison Wiles

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.

The following faculty stated they have no financial relationships with commercial interests:

  • Dr. Jacob Bornstein
  • Dr. Ruby Nguyen
  • Dr. Colleen Stockdale
  • Dr. Pamela Morrison Wiles

The following faculty have financial relationships with commercial interests: 

  • Dr. Andrew Goldstein-- Consultant: Emotional Brain, SST; Investigator: Palatin, Bayer
Bernard Abrams, MD, content reviewer, Jennifer Hodge, Project Manager, Dannemiller; and Lisa Goldstein and Phyllis Mate, NVA have no financial relationships with commercial interests.To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

Off-label statement

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller or the National Vulvodynia Association. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject.